• Latest
Govt issues alert on painkiller Meftal

Govt issues alert on painkiller Meftal

8 December 2023
News diary

1. IIM Ranchi sets new placement record with ₹1.2 crore EMBA offer 2. Centre moves to grant ‘Vande Mataram’ status equal to National Anthem and more stories

6 May 2026
Centre moves to grant ‘Vande Mataram’ status equal to National Anthem

Centre moves to grant ‘Vande Mataram’ status equal to National Anthem

6 May 2026
IIM Ranchi sets new placement record with ₹1.2 crore EMBA offer

IIM Ranchi sets new placement record with ₹1.2 crore EMBA offer

6 May 2026
JAC scraps Class 10 exams after Hindi, Science paper leaks

JAC 12th result 2026 declared: Arts records 96.14% pass percentage, science 82.92%

6 May 2026
Jharkhand Govt trying to bury ₹10,000 crore treasury scam: BJP

Jharkhand Govt trying to bury ₹10,000 crore treasury scam: BJP

6 May 2026
DISHA committee member targets Jharkhand govt over crime, corruption

DISHA committee member targets Jharkhand govt over crime, corruption

6 May 2026
The Jharkhand Story
  • Advertise with us
  • Breaking
  • Governance
  • Politics
  • Education
  • Crime
  • Judiciary
  • Climate & Wildlife
  • Industries & Mining
Thursday, May 7, 2026
  • Home
  • Election
  • Politics
  • Judiciary
  • Governance
  • Crime
  • Industries & Mining
  • Health
  • Tribal Issues
  • Education
  • Sports
  • More
    • Life Style
    • Jobs & Careers
    • Tourism
    • Opinion
    • Infrastructure
    • Science & Tech
    • Climate & Wildlife
    • Corruption
    • News Diary
No Result
View All Result
The Jharkhand Story
No Result
View All Result
Home Breaking

Govt issues alert on painkiller Meftal

Jharkhand Story by Jharkhand Story
8 December 2023
in Breaking, Health
Govt issues alert on painkiller Meftal
Share on FacebookShare on Twitter

THE JHARKHAND STORY DESK

 

New Delhi, Dec 8: The Indian Pharmacopoeia Commission (IPC) has issued an alert regarding the common painkiller, Meftal.

In a release issued on Thursday, it said that people must take the drug only after consulting a doctor as it contains mefenamic acid which can trigger adverse reactions like DRESS syndrome, etc. Meftal is a commonly used drug for menstrual cramps and rheumatoid arthritis.

“Healthcare professionals, patients, and consumers are advised to closely monitor the possibility of the above adverse drug reactions (ADR) associated with the use of the above-suspected drug,” the alert said.

The alert comes as Meftal was rapidly becoming a common painkiller in homes with people using it without much caution to get some relief from muscle and joint pain.

The primary constituent of Meftal is Mefenamic acid, a pain-relieving agent employed for the alleviation of muscle and joint pain as well as menstrual pain. Additionally, it exhibits efficacy in mitigating sore throats, nerve pain, and muscle aches.

What is DRESS syndrome

“The Drug Rash with Eosinophilia and Systemic Symptoms (DRESS syndrome) is a unique and severe idiosyncratic response to a medication, marked by a protracted onset period. It was linked to medications such as abacavir, allopurinol, and lamotrigine. Subsequently, it manifests through a diverse array of clinical symptoms, typically including fever, skin rash, lymphadenopathy, eosinophilia, and a spectrum of systemic manifestations ranging from mild to severe,” said Dr. Sidhant Goel, The Hans Foundation, Nalagarh.

Tags: health alertMeftalndian Pharmacopoeia Commission
ShareTweetShareSendSendShare
Next Post
PM Modi

PM on cash recovery from Jharkhand Congress MP:  Every penny will have to be returned, this is Modi's guarantee

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Advertise with us
  • Breaking
  • Governance
  • Politics
  • Education
  • Crime
  • Judiciary
  • Climate & Wildlife
  • Industries & Mining
Mail us : thejharkhandstory@gmail.com

© 2025 The Jharkhand Story

No Result
View All Result
  • Home
  • Election
  • Politics
  • Judiciary
  • Governance
  • Crime
  • Industries & Mining
  • Health
  • Tribal Issues
  • Education
  • Sports
  • More
    • Life Style
    • Jobs & Careers
    • Tourism
    • Opinion
    • Infrastructure
    • Science & Tech
    • Climate & Wildlife
    • Corruption
    • News Diary